5-(3-chlorophenyl)-1,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinecarbonitrile | 450841-35-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 5-(3-chlorophenyl)-1,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinecarbonitrile
• 英文别名: 5-(3-Chlorophenyl)-1,6-dimethyl-2-oxopyridine-3-carbonitrile
• CAS: 450841-35-7
• 化学式: C₁₄H₁₁ClN₂O
• 分子量: 258.707
• InChiKey: HFTQZNBALRDDSJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  44.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-(3-chlorophenyl)-1,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinecarbonitrile 在 N-溴代丁二酰亚胺(NBS) 、 偶氮二异丁腈 、 溶剂黄146 、 silver(l) oxide 作用下， 以 四氯化碳 、 二氯甲烷 为溶剂， 生成 5-(3-Chloro-phenyl)-6-[(4-cyano-phenyl)-(3H-imidazol-4-yl)-methoxymethyl]-1-methyl-2-oxo-1,2-dihydro-pyridine-3-carbonitrile
  参考文献：
  名称：

  Pyridone-Containing farnesyltransferase inhibitors: synthesis and biological evaluation

  摘要：

  Farnesyltransferase inhibitors (FTIs) have been developed as potential anti-cancer agents due to their efficacy in blocking malignant growth in a variety of murine models of human tumors. To that end, we have developed a series of pyridone farnesyltransferase inhibitors with potent in vitro and cellular activity. The synthesis, SAR and biological properties of these compounds will be discussed. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.08.058
• 作为产物：
  描述：

  3-氰基-6-甲基-2(1H)-吡啶酮 在 N-溴代丁二酰亚胺(NBS) 、 四(三苯基膦)钯 、 sodium carbonate 、 potassium carbonate 、 lithium chloride 作用下， 以 乙醇 、 1,2-二氯乙烷 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 生成 5-(3-chlorophenyl)-1,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinecarbonitrile
  参考文献：
  名称：

  Pyridone-Containing farnesyltransferase inhibitors: synthesis and biological evaluation

  摘要：

  Farnesyltransferase inhibitors (FTIs) have been developed as potential anti-cancer agents due to their efficacy in blocking malignant growth in a variety of murine models of human tumors. To that end, we have developed a series of pyridone farnesyltransferase inhibitors with potent in vitro and cellular activity. The synthesis, SAR and biological properties of these compounds will be discussed. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.08.058

文献信息

• Farnesyltransferase inhibitors
  申请人：——

  公开号：US20030087940A1

  公开（公告）日：2003-05-08

  Substituted imidazoles and thiazoles having the formula 1 are useful for inhibiting farnesyltransferase. Also disclosed are farnesyltransferase-inhibiting compositions and methods of inhibiting farnesyltransferase in a patient.

  具有以下化学式的取代咪唑和噻唑对抑制法尼基转移酶具有用处。还公开了抑制法尼基转移酶的组合物和在患者中抑制法尼基转移酶的方法。
• Farnesyltransferase Inhibitors
  申请人：Claiborne K. Akiyo

  公开号：US20060264476A1

  公开（公告）日：2006-11-23

  Substituted imidazoles and thiazoles having the formula are useful for inhibiting farnesyltransferase. Also disclosed are farnesyltransferase-inhibiting compositions and methods of inhibiting farnesyltransferase in a patient.

  具有以下公式的取代咪唑和噻唑对于抑制法尼酰转移酶是有用的。还披露了抑制法尼酰转移酶的组合物和在患者中抑制法尼酰转移酶的方法。
• FARNESYLTRANSFERASE INHIBITORS
  申请人：ABBOTT LABORATORIES

  公开号：EP1339695B1

  公开（公告）日：2006-04-19
• US7211595B2
  申请人：——

  公开号：US7211595B2

  公开（公告）日：2007-05-01
• US7323570B2
  申请人：——

  公开号：US7323570B2

  公开（公告）日：2008-01-29